Picard Medical, Inc. Announces Presentation at H.C. Wainwright Global Investment Conference
Picard Medical (NYSE American: PMI) announced its upcoming participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will be held from September 8-10, 2025, at the Lotte New York Palace Hotel in a hybrid format featuring both in-person and virtual sessions.
CEO Patrick NJ Schnegelsberg will deliver an in-person company presentation on September 10th at 1:30 pm. The presentation will be webcasted live and available for replay through Picard's website in the Investor Overview/Events section.
Picard Medical (NYSE American: PMI) ha annunciato la sua partecipazione alla H.C. Wainwright 27th Annual Global Investment Conference. L'evento si svolgerà dall'8 al 10 settembre 2025 presso il Lotte New York Palace Hotel in formato ibrido, con sessioni sia in presenza che virtuali.
Il CEO Patrick NJ Schnegelsberg terrà una presentazione in presenza il 10 settembre alle 13:30. La presentazione sarà trasmessa in diretta via webcast e sarà disponibile in replica nella sezione Investor Overview/Events del sito web di Picard.
Picard Medical (NYSE American: PMI) anunció su próxima participación en la H.C. Wainwright 27th Annual Global Investment Conference. El evento se celebrará del 8 al 10 de septiembre de 2025 en el Lotte New York Palace Hotel en formato híbrido, con sesiones presenciales y virtuales.
El CEO Patrick NJ Schnegelsberg ofrecerá una presentación presencial el 10 de septiembre a la 1:30 p.m. La presentación se transmitirá en vivo por webcast y quedará disponible en repetición en la sección Investor Overview/Events del sitio web de Picard.
Picard Medical (NYSE American: PMI)가 H.C. Wainwright 제27회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 행사는 2025년 9월 8일부터 10일까지 롯데 뉴욕 팰리스 호텔에서 대면 및 온라인을 병행하는 하이브리드 형식으로 열립니다.
CEO Patrick NJ Schnegelsberg가 9월 10일 오후 1시 30분에 대면 회사 발표를 진행합니다. 발표는 웹캐스트로 생중계되며 Picard 웹사이트의 Investor Overview/Events 섹션에서 재시청할 수 있습니다.
Picard Medical (NYSE American: PMI) a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. L'événement se tiendra du 8 au 10 septembre 2025 au Lotte New York Palace Hotel, au format hybride avec des sessions en présentiel et virtuelles.
Le CEO Patrick NJ Schnegelsberg présentera en personne le 10 septembre à 13h30. La présentation sera diffusée en direct par webcast et accessible en replay dans la rubrique Investor Overview/Events du site web de Picard.
Picard Medical (NYSE American: PMI) kündigte seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference an. Die Veranstaltung findet vom 8. bis 10. September 2025 im Lotte New York Palace Hotel in einem hybriden Format mit Präsenz- und virtuellen Sitzungen statt.
CEO Patrick NJ Schnegelsberg wird am 10. September um 13:30 Uhr eine Präsenzpräsentation halten. Die Präsentation wird live per Webcast übertragen und kann anschließend im Bereich Investor Overview/Events auf der Website von Picard als Wiederholung abgerufen werden.
- None.
- None.
TUCSON, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that Patrick NJ Schnegelsberg, Chief Executive Officer, will present in-person at the H.C. Wainwright 27th Annual Global Investment Conference being held both in-person and virtually from September 8 -10, 2025 at the Lotte New York Palace Hotel.
Presentation information is below:
H.C. Wainwright Annual Global Investment Conference
Presentation date: September 10th
Presentation time: 1:30 pm
Format: in-person; live, webcasted Company presentation with reply
To listen to the presentation live or via replay, please visit the Investor Overview/Events section of the Picard website here
About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ
When is Picard Medical (PMI) presenting at the H.C. Wainwright Conference 2025?
Who will represent Picard Medical at the H.C. Wainwright Conference?
How can investors access Picard Medical's H.C. Wainwright Conference presentation?
What type of format will Picard Medical's presentation have at the conference?
